FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1993803325> ?p ?o ?g. }

• W1993803325 endingPage "1207" @default.
• W1993803325 startingPage "1194" @default.
• W1993803325 abstract "Abstract Monoclonal antibody (mAb) 38C2 belongs to a group of catalytic antibodies that were generated by reactive immunization and contains a reactive lysine. 38C2 catalyzes aldol and retro‐aldol reactions, using an enamine mechanism, and mechanistically mimics natural aldolase enzymes. In addition, mAb 38C2 can be redirected to target integrins α v β 3 and α v β 5 through the formation of a covalent bond between a β‐diketone derivative of an arginine–glycine–aspartic acid (RGD) peptidomimetic and the reactive lysine residue in the antibody combining site to provide the chemically programmed mAb cp38C2. In this study, we investigated the potential of enhancing the activity of receptor‐binding small molecule drug (SCS‐873) through antibody conjugation. Using a M21 human melanoma xenograft model in nude mice, cp38C2 inhibited the growth of the tumor by ˜81%. The chemically programmed antibody was shown to be highly active at a low concentration while SCS‐873 alone was ineffective even at dosages ˜1,000‐fold higher than those used for the chemically programmed antibody. In vitro programming of the catalytic antibody was shown to be as effective as in vivo programming. In an experimental metastasis assay, treatment with mAb cp38C2 significantly prolonged overall survival of tumor‐bearing severe combined immuno‐deficient (SCID) mice when compared to treatment with unprogrammed mAb 38C2, SCS‐873 alone or the integrin‐specific monoclonal antibody LM609. In vitro, cp38C2 inhibited human and mouse endothelial and human melanoma cell adhesion, migration and invasion. Additionally, cp38C2 inhibited human and mouse endothelial cell proliferation and was active in complement‐dependent cytotoxicity assays. These studies establish the potential of chemically programmed monoclonal antibodies as a novel and effective class of immunotherapeutics that combine the merits of traditional small molecule drug design with immunotherapy. © 2006 Wiley‐Liss, Inc." @default.
• W1993803325 created "2016-06-24" @default.
• W1993803325 creator A5001087538 @default.
• W1993803325 creator A5031207478 @default.
• W1993803325 creator A5062956659 @default.
• W1993803325 creator A5065812703 @default.
• W1993803325 creator A5076188773 @default.
• W1993803325 date "2006-06-05" @default.
• W1993803325 modified "2023-10-18" @default.
• W1993803325 title "Small molecule drug activity in melanoma models may be dramatically enhanced with an antibody effector" @default.
• W1993803325 cites W10444853 @default.
• W1993803325 cites W147592962 @default.
• W1993803325 cites W1524285426 @default.
• W1993803325 cites W1595810968 @default.
• W1993803325 cites W1899213809 @default.
• W1993803325 cites W1970300303 @default.
• W1993803325 cites W1970880029 @default.
• W1993803325 cites W1971040598 @default.
• W1993803325 cites W1975182459 @default.
• W1993803325 cites W1996537616 @default.
• W1993803325 cites W2001753204 @default.
• W1993803325 cites W2003366243 @default.
• W1993803325 cites W2014825000 @default.
• W1993803325 cites W2018159680 @default.
• W1993803325 cites W2029039850 @default.
• W1993803325 cites W2029231027 @default.
• W1993803325 cites W2036697376 @default.
• W1993803325 cites W2039317622 @default.
• W1993803325 cites W2047987451 @default.
• W1993803325 cites W2050302779 @default.
• W1993803325 cites W2062245523 @default.
• W1993803325 cites W2063037691 @default.
• W1993803325 cites W2063330553 @default.
• W1993803325 cites W2088929622 @default.
• W1993803325 cites W2090585102 @default.
• W1993803325 cites W2093867530 @default.
• W1993803325 cites W2100363932 @default.
• W1993803325 cites W2113267611 @default.
• W1993803325 cites W2114152534 @default.
• W1993803325 cites W2114286636 @default.
• W1993803325 cites W2114763381 @default.
• W1993803325 cites W2117020898 @default.
• W1993803325 cites W2134649580 @default.
• W1993803325 cites W2197400499 @default.
• W1993803325 cites W2512688461 @default.
• W1993803325 cites W2950722634 @default.
• W1993803325 cites W4229859386 @default.
• W1993803325 cites W4250428608 @default.
• W1993803325 doi "https://doi.org/10.1002/ijc.21924" @default.
• W1993803325 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16570283" @default.
• W1993803325 hasPublicationYear "2006" @default.
• W1993803325 type Work @default.
• W1993803325 sameAs 1993803325 @default.
• W1993803325 citedByCount "39" @default.
• W1993803325 countsByYear W19938033252012 @default.
• W1993803325 countsByYear W19938033252013 @default.
• W1993803325 countsByYear W19938033252014 @default.
• W1993803325 countsByYear W19938033252015 @default.
• W1993803325 countsByYear W19938033252016 @default.
• W1993803325 countsByYear W19938033252017 @default.
• W1993803325 countsByYear W19938033252018 @default.
• W1993803325 countsByYear W19938033252023 @default.
• W1993803325 crossrefType "journal-article" @default.
• W1993803325 hasAuthorship W1993803325A5001087538 @default.
• W1993803325 hasAuthorship W1993803325A5031207478 @default.
• W1993803325 hasAuthorship W1993803325A5062956659 @default.
• W1993803325 hasAuthorship W1993803325A5065812703 @default.
• W1993803325 hasAuthorship W1993803325A5076188773 @default.
• W1993803325 hasBestOaLocation W19938033251 @default.
• W1993803325 hasConcept C109316439 @default.
• W1993803325 hasConcept C124790011 @default.
• W1993803325 hasConcept C153911025 @default.
• W1993803325 hasConcept C159654299 @default.
• W1993803325 hasConcept C170493617 @default.
• W1993803325 hasConcept C185592680 @default.
• W1993803325 hasConcept C195616568 @default.
• W1993803325 hasConcept C195687474 @default.
• W1993803325 hasConcept C202751555 @default.
• W1993803325 hasConcept C203014093 @default.
• W1993803325 hasConcept C2779281246 @default.
• W1993803325 hasConcept C502942594 @default.
• W1993803325 hasConcept C542903549 @default.
• W1993803325 hasConcept C55493867 @default.
• W1993803325 hasConcept C86803240 @default.
• W1993803325 hasConceptScore W1993803325C109316439 @default.
• W1993803325 hasConceptScore W1993803325C124790011 @default.
• W1993803325 hasConceptScore W1993803325C153911025 @default.
• W1993803325 hasConceptScore W1993803325C159654299 @default.
• W1993803325 hasConceptScore W1993803325C170493617 @default.
• W1993803325 hasConceptScore W1993803325C185592680 @default.
• W1993803325 hasConceptScore W1993803325C195616568 @default.
• W1993803325 hasConceptScore W1993803325C195687474 @default.
• W1993803325 hasConceptScore W1993803325C202751555 @default.
• W1993803325 hasConceptScore W1993803325C203014093 @default.
• W1993803325 hasConceptScore W1993803325C2779281246 @default.
• W1993803325 hasConceptScore W1993803325C502942594 @default.
• W1993803325 hasConceptScore W1993803325C542903549 @default.
• W1993803325 hasConceptScore W1993803325C55493867 @default.

• next